Biotech Values

[kaivamei]

He said mC was in "after-review" at FDA.

Does anyone know what this might mean? "After-review" is not a term I am used to hearing. It almost sounds like a page out of Teva's book -- a way of saying that the main phase of review is complete, and only some bureaucratic formalities remain.

In any case, that sounded like his way of indicating that, yes, mC approval could indeed be a 2011 event.